Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2017-04-25 Annual Report
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Bone Therapeutics_Annual Report_2016 _FR-LD_17259.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'Rapport annuel' (Annual Report) and functions as a reference document under Belgian law. It contains a comprehensive table of contents covering risk factors, financial information, business development, and corporate strategy. Given the document length (over 1 million characters) and the inclusion of substantive financial and operational disclosures, it qualifies as a full Annual Report rather than a mere announcement. FY 2016
2017-04-25 French
PR_2017-03-16_BT_FY2016_EN_Final_Long.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a comprehensive report detailing the full-year financial results for 2016, including an income statement, balance sheet, and detailed management discussion and analysis of operational and financial performance. It is not a short announcement (it exceeds 38,000 characters) and contains substantive financial data, which distinguishes it from a simple report publication announcement (RPA) or a regulatory filing (RNS). It functions as an annual financial report for the period ending December 31, 2016. FY 2016
2017-03-16 English
PR_2017-03-16_BT_FY2016_FR_Final_Long.pdf
Earnings Release Classification · 95% confidence The document is a detailed announcement of annual financial results for Bone Therapeutics for the fiscal year 2016. It includes key financial highlights, operational updates, management changes, and a summary table of financial statements (income statement, cash flow). While it contains financial data, it is structured as an initial press release/announcement of results rather than the full, audited Annual Report (10-K) document itself. Therefore, it is classified as an Earnings Release. FY 2016
2017-03-16 French
Communiqués de mise à disposition de documents / Modalités de mise à disposition du rapport financier annuel
Earnings Release Classification · 95% confidence The document is a press release from Bone Therapeutics announcing its 2016 annual financial results. It includes key financial highlights, operational updates, and management commentary. While it contains financial data, it is structured as an initial announcement (Earnings Release) rather than a full statutory Annual Report (10-K). It provides a summary of the fiscal year performance and invites investors to a conference call, which is characteristic of an Earnings Release. FY 2016
2017-03-16 French
Document availability communications / Annual financial report
Earnings Release Classification · 95% confidence The document is a press release titled 'Bone Therapeutics Reports Full Year 2016 Results'. It contains key financial highlights, operating results, and a summary table of financial data for the fiscal year ending 31 December 2016. While it provides financial data, it is structured as an initial announcement of results (Earnings Release) rather than the full, comprehensive Annual Report (10-K). It includes forward-looking statements and contact information typical of an earnings release. FY 2016
2017-03-16 English
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 99% confidence The document is explicitly titled as a "Press Release" dated March 10, 2017. The core content announces the company's participation schedule in several upcoming "key investor conferences" (BioCapital Europe, Portzamparc Mid & Small Cap Conference, KBC Securities Healthcare Conference, etc.). This type of announcement, detailing future investor engagement events, is best classified as an Investor Presentation (IP) or related investor communication, but none of the definitions perfectly match an announcement *about* attending conferences. However, the closest fit among the provided codes that relates to investor engagement and future outlook/strategy presentation is Investor Presentation (IP), as these conferences are where presentations are typically given. Given the options, and recognizing this is an announcement *about* investor events rather than a formal regulatory filing or a specific report, it aligns most closely with the general category of investor-facing material. If the document were the actual presentation slides, IP would be certain. Since it is an announcement of attendance, it is a strong indicator of investor relations activity. Alternatively, it could be a Regulatory Filing (RNS) as a general announcement, but IP is more specific to the context of investor conferences. I will select IP as the primary intent is investor communication regarding future events.
2017-03-10 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.